Becton Dickinson (BDX) announced full enrollment of the iliac artery patient cohort in its AGILITY investigational device exemption study, a prospective, multi-center study evaluating the Revello vascular covered stent in patients with peripheral arterial disease.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BDX:
- BDX Upcoming Earnings Report: What to Expect?
- Becton Dickinson receives FDA clearance, CE mark for enteric bacterial panels
- BD’s New Vascular Access Study: What Investors Need to Know
- BDX’s SiteRite 9 Study: A New Frontier in Ultrasound-Guided Vascular Access
- Becton, Dickinson’s New Study on Sepsis Diagnostic Vials: Market Implications